Research Article
CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome
Table 1
Clinical characteristics of patients with thrombotic APS and controls.
| | Parameter | Thrombotic
APS () | aPL positive controls () | SLE controls () | Healthy controls () | P |
| | Age, y, mean (range) | 50 (29–78) | 43 (37–59) | 42 (30–69) | 48 (30–75) | 0.17 |
| | Sex | | | | | | | Men (%) | 28.9 | 21.4 | 25 | 36.5 | 0.87 | | Women (%) | 71.1 | 78.6 | 75 | 63.5 | |
| | Risk factors of thrombosis | 15 (39) | 0 | 0 | 0 | — |
| | Thrombotic event | | | | | | | Stroke | 7 (18.42%) | 0 | 0 | 0 | — | | DVT | 4 (10.53%) | 0 | 0 | 0 | — | | CRVT | 4 (10.53%) | 0 | 0 | 0 | — | | Pulmonary embolism | 3 (7.89%) | 0 | 0 | 0 | — | | Hepatic vein thrombosis | 1 (2.63%) | 0 | 0 | 0 | — | | Thrombophlebitis | 1 (2.63%) | 0 | 0 | 0 | — | | Different combinations of thrombotic events | 12 (31.58%) | 0 | 0 | 0 | — | | Thrombotic events and miscarriage | 4 (10.53%) | 0 | 0 | 0 | — | | Other | 2 (5.26%) | 0 | 0 | 0 | — | | Baseline disease | | | | | | | Lupus like disease | 0 | 4 (28.6%) | 0 | 0 | — | | Sjogren’s syndrome | 0 | 1 (7.1%) | 0 | 0 | — | | Systemic vasculitis | 0 | 1 (7.1%) | 0 | 0 | — | | Rheumatoid arthritis | 0 | 1 (7.1%) | 0 | 0 | — | | Thrombocytopenia | 9 (23.7%) | 3 (21.4%) | 4 (25%) | 0 | — | | Cutaneous lupus | 0 | 1 (7.1%) | 0 | 0 | — | | UCTD | 0 | 3 (21.4%) | 0 | 0 | — | | Clinical and biological markers | | | | | | | CRP (mg/dL) | 2.24 ± 6.84 | 0.32 ± 0.34 | 1.47 ± 2.82 | — | 0.55 | | ESR (mm/hour) | 20.5 ± 24.8 | 9.9 ± 9.9 | 14.3 ± 8.9 | — | 0.28 | | RF (IU/mL) | 26.4 ± 20.4 | 75.4 ± 183.9 | 23.4 ± 11.9 | — | 0.42 | | SLEDAI index | — | — | 2.3 ± 1.8 | — | — |
|
|
CRP: C-reactive protein; CRVT: central retinal vein thrombosis; DVT: deep vein thrombosis; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; UDCD: undifferentiated connective-tissue disease.
|
